Bioage Labs (BIOA) closed at $5.55 on November 13, 2026, down 1.8% from the previous close, on volume of 403,098 shares (30-day average 791,445).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 23, 2026 | Call Spread | 15-Jan-275 : 10 C | 400 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
BioAge Labs to Present at Upcoming Investor Conferences
Globe Newswire (Wed, 11-Nov 8:00 AM ET)
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Thu, 5-Nov 4:30 PM ET)
BioArctic collaborator Novartis terminates agreement
PRNewswire (Mon, 2-Nov 4:14 PM ET)
BioArctic's Nomination Committee appointed
PRNewswire (Fri, 30-Oct 10:21 AM ET)
Globe Newswire (Wed, 14-Oct 8:00 AM ET)
Globe Newswire (Tue, 8-Sep 8:00 AM ET)
Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
PRNewswire (Mon, 31-Aug 11:57 AM ET)
BioAge’s BGE-102 Achieves Over 85% Reduction in hsCRP, Setting New Benchmark in Inflammation Trials
Market Chameleon (Tue, 21-Apr 3:35 AM ET)
Market Chameleon (Mon, 12-Jan 6:17 AM ET)
Market Chameleon (Thu, 4-Dec 4:55 AM ET)
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
Bioage Labs trades on the NASDAQ stock market under the symbol BIOA.
As of November 13, 2026, BIOA stock price declined to $5.55 with 403,098 million shares trading.
BIOA has a beta of 1.84, meaning it tends to be more sensitive to market movements. BIOA has a correlation of 0.04 to the broad based SPY ETF.
BIOA has a market cap of $254.73 million. This is considered a Small Cap stock.
Last quarter Bioage Labs reported $298,000 in Revenue and -$.73 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.09.
The top ETF exchange traded funds that BIOA belongs to (by Net Assets): VTI, IWM, VXF, XPH, IWN.
BIOA has underperformed the market in the last year with a price return of -28.1% while the SPY ETF gained +13.4%. BIOA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -46.8% and -5.5%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
BIOA support price is $5.31 and resistance is $5.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIOA shares will trade within this expected range on the day.
